Krystal Biotech (KRYS) Stock Analysis: AI Score & Alternative Data
KRYS alt-data: revenue climbing, job postings lagging
Is Krystal Biotech a buy right now? The alternative data says hold. This KRYS stock analysis is built on the 25+ alternative data signals AltIndex tracks on Krystal Biotech every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 57/100: a Hold. The stock trades at $326.45 with a $10B market cap.
The bullish side of the 90-day ledger: revenue up 33.3% YoY to $120M, and headcount (according to LinkedIn) up 5.9% to 321 employees. The drag: job postings down 40.0% to 12 open roles, just 59% of employees report a positive business outlook, and web traffic down 9.3% to 12K monthly visits. That tension is what keeps the score mid-range.
KRYS’s broader alt-data profile also covers X followers (1K), and sentiment (100/100). Every signal links to its own page with full history, the KRYS technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on KRYS is just below.
Krystal Biotech AI Stock Analysis
Krystal Biotech, Inc. is a biopharmaceutical company dedicated to developing and commercializing gene therapy medicines. The company is focused on developing treatments for patients suffering from devastating dermatologic diseases.
Analysis generated August 5, 2026.
Recent Krystal Biotech Stock Alerts
|
Krystal Biotech | August 3 Employee Rating is up by 2.9% over the last month. |
|
Krystal Biotech | August 3 Business Outlook among employees is up by 7.3% over the last month. |
|
Krystal Biotech | August 3 Price is down by -7.2% in the last 24h. |
|
Krystal Biotech | July 31 Price is down by -6.1% in the last 24h. |
Krystal Biotech Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 12K | 9.3% | |
| Job Posts | 12 | 40.0% | |
| LinkedIn Employees | 321 | 5.9% | |
| Employee Recommend | 65 | 14.0% | |
| Business Outlook | 59 | 20.4% | |
| Sentiment | 100 | 0% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 1 | 88.9% | |
| Stocktwits Mentions | 8 | 11.1% | |
| News Mentions | 0 | 100.0% | |
| Stocktwits Subscribers | 2K | 3.4% | |
| 4chan Mentions | 0 | N/A | |
| X Followers | 1K | 2.4% |
About Krystal Biotech (KRYS)
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States.
| Price | $326.45 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $10B |
| Year Range | $137 – $378 |
| Dividend Yield | 0% |
| PE Ratio | 41.0 |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Krystal Biotech News
View more → |
Krystal Biotech Shares Fall Over 10% After Q2 Results Despite VYJUVEK Revenue Growth and Pipeline ProgressAugust 3 - Ibtimes.com.au |
Krystal Biotech Shares Slide Despite Earnings Beat as Revenue Misses ForecastsAugust 3 - Advfn.com |
|
Krystal Biotech Announces Second Quarter 2026 Financial and Operating ResultsAugust 3 - GlobeNewswire |
|
Krystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600July 20 - PRNewswire |
|
The Brown Capital Management Small Company Fund Bets on Krystal Biotech (KRYS) for Its Resilient Revenue StreamJune 24 - Yahoo Entertainment |
|
Krystal Biotech Earnings & Financial Performance
View all earnings →Krystal Biotech Insider Trading Activity
View all →| Thomas John Charles filed to sell 0 shares at $0.0. Jun 25 '26 |
| Krishnan Krish S filed to sell 1,450,253 shares at $0.0. Jun 4 '26 |
| Krishnan Krish S filed to sell 1,474,117 shares at $0.0. Jun 4 '26 |
| Krishnan Krish S filed to sell 1,474,933 shares at $0.0. Jun 4 '26 |
| Krishnan Krish S filed to sell 1,473,573 shares at $0.0. Jun 4 '26 |
Krystal Biotech Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Christopher Jacobs |
Jan 20, 23 | Buy | $8K+ |
Stocks Similar to Krystal Biotech
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Bio-RadBIO |
$352.47 2.9% | $9B | 51 |
 |
Praxis Precision Medicines IncPRAX |
$360.76 2.5% | $10B | 53 |
 |
AvantorAVTR |
$13.59 3.1% | $9B | 43 |
 |
Kymera TherapeuticsKYMR |
$107.52 1.0% | $9B | 62 |
 |
Crinetics PharmaceuticalsCRNX |
$84.08 0.2% | $9B | 48 |
Explore Krystal Biotech Data
Frequently Asked Questions: Krystal Biotech (KRYS)
Krystal Biotech has an AltIndex AI Score of 57/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
57/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Krystal Biotech (KRYS) stock is $326.45 with a market cap of $10B.
As of today, Krystal Biotech’s PE (Price to Earnings) ratio is 41.0.
View the latest Krystal Biotech insider transactions to see recent buying and selling activity by company executives and directors.
Check the Krystal Biotech congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The KRYS stock price chart above shows Krystal Biotech’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Krystal Biotech technical analysis for RSI, moving averages, and more.
See the stocks similar to Krystal Biotech section on this page for companies in the same industry ranked by market cap and AI Score.
